UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/806,683	06/06/2003	Michael Albert Strobel	101918.56959C1	1628
23911 CROWELL &	7590 09/21/2007 MORING LLP		EXAMINER	
INTELLECTUAL PROPERTY GROUP			PESELEV, ELLI	
P.O. BOX 14300 WASHINGTON, DC 20044-4300			ART UNIT	PAPER NUMBER
	· .		1623	
			MAIL DATE	DELIVERY MODE
			09/21/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/806,683	STROBEL, MICHAEL ALBERT		
Examiner	Art Unit		
Elli Peselev	1623		

Before the I filling of all Appeal Brief	Examiner	Art Unit					
	Elli Peselev	1623					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
THE REPLY FILED 06 September 2007 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.							
1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:							
 a) The period for reply expires 3 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. 							
Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).							
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL							
2. The Notice of Appeal was filed on A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).							
AMENDMENTS 2							
3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below);							
 (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or 							
(d) They present additional claims without canceling a corresponding number of finally rejected claims.							
NOTE: (See 37 CFR 1.116 and 41.33(a)). 4 The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).							
 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendment canceling the 							
7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of							
now the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows:							
Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1,2,5-7,10-12 and 15-23.							
Claim(s) withdrawn from consideration:							
AFFIDAVIT OR OTHER EVIDENCE							
 The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 	t before or on the date of filing a No d sufficient reasons why the affidav	otice of Appeal will <u>no</u> it or other evidence is	t be entered and necessary and				
9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).							
10. The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER							
11. The request for reconsideration has been considered bu See Continuation Sheet.		n condition for allowar	nce because:				
12. ☐ Note the attached Information Disclosure Statement(s).13. ☐ Other:	(PTO/SB/08) Paper No(s).						
		ELLI PËSEI	legt.				
		PRIMARY EXA	MINER				

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06) Continuation of 11. does NOT place the application in condition for allowance because: Applicant contends that the use of a pyrrolidone, as required by Komer "would materially affect the basic and novel characteristic(s) of the claimed solution. This argument has not been found persuasive since applicant has not presented any evidence in verified form showing that a pyrrolidone disclosed by Komer would materially affect the basic and novel characteristics of the claimed invention. Note that on page 8 of the specification, last line and page 9, lines 1-6, it is stated that the art on introducing ivermectin to animals does not currently possess a formulation that is stable in water without utilizing compounds similar to benzyl alcohol. The specification on page 9, lines 15-21 states that the present formulation does not require the presence of benzyl alcohol. The specification does not teach that the claime composition does not require the presence of a pyrrolidone. Further, Komer also teach that a mixture of propylene and glycol for dissolution of ivermectin in the absence of pyrrolidone was known in the art at the time the claimed invention was made (see column 1, last two lines).